Technical Analysis for CYTK - Cytokinetics, Incorporated

Grade Last Price % Change Price Change
B 25.93 2.77% 0.70
CYTK closed up 2.77 percent on Friday, May 14, 2021, on 52 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CYTK trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 2.77%
MACD Bullish Centerline Cross Bullish 2.77%
Up 3 Days in a Row Strength 2.77%
50 DMA Support Bullish 6.62%
Oversold Stochastic Weakness 6.62%
MACD Bearish Centerline Cross Bearish 9.09%
Crossed Above 50 DMA Bullish 9.09%
Older End-of-Day Signals for CYTK ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 14 hours ago
Up 2% about 15 hours ago
20 DMA Support about 15 hours ago
Rose Above Previous Day's High about 15 hours ago
Up 1% about 15 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cytokinetics, Incorporated Description

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diseases Clinical Development Disease Neuroscience Dysfunction Product Design Heart Failure Anatomy Serious Diseases Amyotrophic Lateral Sclerosis Cytokine Molecule Therapeutics Nervous System Drug Design Orphan Drug Treatment Of Heart Failure Medicinal Product Treatment Of Serious Diseases

Is CYTK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 30.14
52 Week Low 14.71
Average Volume 869,943
200-Day Moving Average 21.21
50-Day Moving Average 24.06
20-Day Moving Average 25.22
10-Day Moving Average 24.40
Average True Range 1.26
ADX 18.95
+DI 27.83
-DI 17.11
Chandelier Exit (Long, 3 ATRs ) 24.35
Chandelier Exit (Short, 3 ATRs ) 26.55
Upper Bollinger Band 27.58
Lower Bollinger Band 22.87
Percent B (%b) 0.65
BandWidth 18.68
MACD Line 0.13
MACD Signal Line 0.20
MACD Histogram -0.0777
Fundamentals Value
Market Cap 1.84 Billion
Num Shares 70.8 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -13.08
Price-to-Sales 19.80
Price-to-Book 8.26
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.45
Resistance 3 (R3) 27.35 26.75 27.19
Resistance 2 (R2) 26.75 26.36 26.80 27.11
Resistance 1 (R1) 26.34 26.13 26.55 26.44 27.02
Pivot Point 25.74 25.74 25.84 25.79 25.74
Support 1 (S1) 25.33 25.35 25.54 25.43 24.84
Support 2 (S2) 24.73 25.12 24.78 24.75
Support 3 (S3) 24.32 24.73 24.67
Support 4 (S4) 24.42